Biogen tweaks confirmatory trial of Alzheimer’s drug AduhelmBiogen and Eisai have expanded the size of the confirmatory trial of their Alzheimer’s drug Aduhelm in order Share XBiogen tweaks confirmatory trial of Alzheimer’s drug Aduhelmhttps://pharmaphorum.com/news/biogen-tweaks-confirmatory-trial-of-alzheimers-drug-aduhelm/
Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDABiogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s Share XBiogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDAhttps://pharmaphorum.com/news/biogen-eisai-alzheimers-drug-lecanemab-fast-tracked-by-fda/
Biogen takes axe to Aduhelm price in a bid to drive take-upBiogen has cut the list price of its Alzheimer’s disease therapy in half from $56,000 to $28,200 a Share XBiogen takes axe to Aduhelm price in a bid to drive take-uphttps://pharmaphorum.com/news/biogen-takes-axe-to-aduhelm-price-in-a-bid-to-drive-take-up/
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisorsThe EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying Share XBiogen’s Alzheimer’s drug Aduhelm is rejected by EU advisorshttps://pharmaphorum.com/news/biogens-alzheimers-drug-aduhelm-is-rejected-by-eu-advisors/
Viagra ‘should be tested as Alzheimer’s therapy’Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a Share XViagra ‘should be tested as Alzheimer’s therapy’https://pharmaphorum.com/news/viagra-should-be-tested-as-alzheimers-therapy/
Novartis takes aim at risky Parkinson’s target with $1.5bn UCB dealNovartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first Share XNovartis takes aim at risky Parkinson’s target with $1.5bn UCB dealhttps://pharmaphorum.com/news/novartis-takes-aim-at-risky-parkinsons-target-with-1-5bn-ucb-deal/
Buoyed by new data, Santhera preps filing for DMD drug vamoroloneA year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular Share XBuoyed by new data, Santhera preps filing for DMD drug vamorolonehttps://pharmaphorum.com/news/buoyed-by-new-data-santhera-preps-filing-for-dmd-drug-vamorolone/
CHMP minded to turn down Alzheimer’s drug Aduhelm, says BiogenBiogen and Eisai have said that the EMA’s human medicines committee looks unlikely recommended approval of their Alzheimer’s Share XCHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogenhttps://pharmaphorum.com/news/chmp-minded-to-turn-down-alzheimers-drug-aduhelm-says-biogen/
AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trialAbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral Share XAbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trialhttps://pharmaphorum.com/news/abbvie-preps-filings-after-abbv-951-tops-oral-parkinsons-drugs-in-trial/
